Medical CBD Roundup

Image | adobe.stock/Tinnakorn

In honor of National CBD Day, Cannabis Science and Technology has compiled a roundup of articles related to CBD medical research:

CBD Study Aids in Relief for Chronic Pain Sufferers

A recently published study explored the potential benefit cannabidiol (CBD) may have on individuals who suffer from chronic pain. The research was published in Cureus, a scientific journal. Researchers a part of the study are connected with the Alabama College of Osteopathic Medicine (Dothan, Alabama).

From Pain to Pimples: The Growing List of Topical Cannabinoid Applications

Cannabis products offer a variety of consumption options for users to choose from, including edibles, joints, vapes, and suppositories. These dosage formats fit different needs and consumer preferences, but cannabis products can also be administered externally through formats such as creams and balms. This feature article from our March/April 2025 issue explores the different applications of cannabidiol (CBD) and other cannabinoids, as well as unique insight from Dr. Dustin Sulak, DO, Founder of Healer.

From Eczema to Parkinson’s: The Latest Healer Webinar on Recent Cannabis Research

On April 30, 2025, Dustin Sulak, DO, founder of Healer, a cannabis education and product resource, presented an analysis on recent research involving cannabis for various conditions.

Study Analyzes Long-Term Effects of Medical Cannabis for Various Conditions

A recently published study analyzed the long-term effects of medical cannabis (MC) for patients in Australia. As the abstract noted, over one million new patients with chronic health conditions in Australia have been prescribed medical cannabis since 2016, and about half of the country’s population has a chronic condition. The study, “Improvements in health-related quality of life are maintained long-term in patients prescribed medicinal cannabis in Australia: The QUEST Initiative 12-month follow-up observational study,” was published in PLOS One in April 2025. Real-world evidence from medical cannabis patients is needed to shape policy and regulation, the introduction noted.

Multiple Sclerosis Patients See Improvement with Vaporized Cannabis Cannabinoids THC and CBD

A recent study published in the Journal of Clinical Medicine investigated vaporized cannabis’s use in patients with multiple sclerosis (MS), which contain standardized percentages of tetrahydrocannabinol (THC) and cannabidiol (CBD).

Researchers in Greece analyzed vaporized cannabis consisting of 13% CBD and 9% THC, with 69 participants. Some of the MS participants were experiencing muscle spasticity, disability progression rate, and bladder dysfunction. These symptoms were measured at baseline and then again at three months and six months.